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initiation of a new DMARD within 60 days of the discontinuation date of the index
biologic; intermittent use of the index biologic--60 days of treatment gap, ‘step-
down’--discontinuation of one of the DMARD therapies from the initial combo
therapy, ‘step-up’--adding a new DMARD for 28 consecutive days. Numbers are
reported in pairs with ETN first and ADA second. RESULTS: Over the 12-month
study period, majority of PsA patients newly initiated ETN/ADA (N2037/2217) had
1 therapy change (65.3%/69.1% with a median time to change: 113/112 days). Among
patients initiated on mono ETN/ADA (N1410/1496), 40.7%/33.5% patients remained
on the index mono therapy, 12.1%/11.6% patients discontinued the treatment, 18.2%/
14.7% patients had intermittent treatment, 7.0%/11.4% switched to another mono
therapy, and 21.9%/29.1% step-up to combo therapy. Among patients initiated on ETN/
ADA in combination with an oral DMARD, 21.4%/26.8% remained on the original
combo therapy, 77.5%/72.7% ‘stepped down’ to a mono therapy, and very few patients
discontinued therapy (0.5%/0.1%) or adopting intermittent biologic therapy
(0.6%/0.3%). CONCLUSIONS: This study suggests that most of the PsA patients
newly initiated on ETN or ADA have a therapy change over the first year.
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OBJECTIVES: To evaluate in daily clinical practice possible changes in perceived
quality of life (QoL) in patients treated with solifenacin and also to investigate
whether the treatment had an impact on the use of incontinence pads. METHODS:
This non-interventional study consisted of one visit at the study centres per pa-
tient and two follow-up questionnaires (13-item QoL and 6-item bother scale,
OAB-q SF) after 3 months and 6 months, answered by the patients at home.
RESULTS: A total of 232 patients were included in the study at 35 centers in Swe-
den. Sixty patients participated at baseline only. The age of patients ranged from 25
to 87 years (mean 64 years). One hundred and sixty-seven patients (97.1%) were
women and 5 patients (2.9%) were men. Almost all of the participating investiga-
tors were specialists in gynecology, which explains the large proportion of women
among the patients. Solifenacin significantly improved self-perceived health-re-
lated quality of life, as measured by the 13-item QoL scale of the OAB-q SF, at 3
months vs. baseline (p .0001) and at 6 months vs. baseline (p .0001) and also
when 6 months and 3 months data were compared (p0.007), in anti-muscarinic
naive OAB patients. Solifenacin significantly improved self-perceived health-re-
lated quality of life, as measured by the 6-item bother scale of the OAB-q SF, at 3
months vs. baseline (p .0001) and at 6 months vs. baseline (p .0001). The mean
use of pads significantly decreased from 19 to 12 pads per week. Solifenacin signif-
icantly decreased the use of pads at 3 months vs. baseline (p .0001) and at 6
months vs. baseline (p.0001). CONCLUSIONS: Solifenacin significantly improved
self-perceived health-related quality of life, as measured by both the 13-item QoL
scale and the 6-item bother scale of the OAB-q SF. Solifenacin significantly de-
creased the use of pads per week.
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OBJECTIVES: Assessing the clinical effectiveness of drugs for rare diseases pres-
ents many challenges for systematic reviewers. Atypical haemolytic uraemic syn-
drome (aHUS) is a rare disease with a worldwide prevalence of between 2.7 and 5.5
per million population. A systematic review was undertaken to assess the clinical
effectiveness of eculizumab for the treatment of aHUS. The aim of this research
was to highlight issues with applying standard systematic review methods to as-
sess clinical effectiveness where the evidence base is not well developed.
METHODS: A systematic review using standard methods was undertaken of ecu-
lizumab for the treatment of aHUS. RESULTS: Standard search methods did not
identify all relevant information and other sources of evidence were used, such as
hand searching and internet searching. Three studies were identified showing
eculizumab to be beneficial in treating aHUS. However serious concerns were iden-
tified with the evidence base in the review. The issues of concern were: lack of a
control group in any of the studies, the use of surrogate outcome measures only,
little information available on comparator treatments, lack of clarity on patient
selection in the trials and no baseline data available for this patient population.
Very little information on eculizumab for aHUS was available in the public domain.
CONCLUSIONS: The issues highlighted here are of concern in the review of other
rare diseases, where information may also be scarce. Guidance is needed on ap-
propriate study designs. There is a need for validated surrogate outcomes and final
patient related outcomes, a need for registries of baseline data, long term follow-up
data and adverse event information to enable the monitoring of the natural course
of the disease. Guidance is need on best practice for the recruitment and selection
of patients for trials of treatments for rare diseases.
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EVALUATION OF MEDICATION-RELATED PROBLEMS IN HEMODIALYSIS
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OBJECTIVES: Patients under hemodialysis (HD) may have many medication-re-
lated problems (MRPs) due to their medical complexity. The study objective was to
identify MRPs experienced by inpatients under HD upon admission in Wang-Fang
hospital in Taiwan.METHODS: Patients on either regular or irregular hemodialysis
from 24th October to 11th November in 2011 were included in this study. Patients
who did not use any drugs were excluded. Demographic and types of MRPs were
assessed by descriptive statistics. RESULTS: A total of 81 patients were evaluated,
and 67 MRPs were identified. Each patient used 11 drugs on average. Patients using
over 12 drugs were at higher risk of occurring MRPs. Among the 67 MRPs, the most
common type of MRP was drug interaction (50.7%), followed by overdose (37.3%).
Pharmacists intervened 17.91% of the MRPs and also kept monitoring 58.2% of the
MRPs. Physicians accepted 91.67% of the pharmacy interventions. Patients under
regular (n67) or irregular HD (n14) were also compared in our study. Different
types of MRPs were shown between the two groups. Drug interaction occurred
more often in patients on regular HD (n32, 47.8%), while overdose was more
commonly discovered in irregular HD group (n7, 50%).CONCLUSIONS:MRPs exist
commonly in HD patients. The study showed that patients using 12 or more drugs
were at higher risk of occurring MRPs. Patients under regular or irregular HD may
have different patterns of MRPs. Pharmacists should be more careful when evalu-
ating these patients’ medications.
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OBJECTIVES: To compare health care resource utilization and costs in OAB adults
receiving fesoterodine, solifenacin or tolterodine in clinical practice in Spain.
METHODS:A retrospective study was designed using primary care electronic med-
ical records from three towns in Spain. Records of patients who initiated OAB
therapy between 2008 and 2010 and with a follow-up of at least 52 weeks were
retained. Patients over 18 of both genders with an OAB diagnosis [ICD-9-CM 596.51]
and a new prescription of fesoterodine, tolterodine or solifenacin were included in
the analyses. All type medical visits (primary care, specialist and emergency room),
absorbents for urinary incontinence, complementary/diagnostic tests and con-
comitant medications related with OAB along with cost of antimuscarinics used
were analyzed (NHS perspective). Comparisons between antimuscarinics were ad-
justed by location, age, sex, time since diagnosis, co-morbidity burden and medi-
cation possession ratio (medication/time), and were compared using univariate
general linear models with bootstrap (1000 re-samples) bias correcting methods to
calculate 95% confidence intervals. RESULTS: A total of 1,971 records (58.3%
women, 70.1 [SD: 10.6] years) were analyzed; 302 treated with fesoterodine, 952
with solifenacin and 717 with tolterodine. Respectively, 17%, 22% and 25% of sub-
jects used absorbents during the study (p0.014). Adjusted mean health care costs
(95% bootstrap CI) were significantly lower with fesoterodine treatment [€1639
(1542; 1725)] compared with solifenacin [€1780 (1699; 1854), p0.022] or tolterodine
[€1893 (1815; 1969), p0.001]. All medical visits costs were also lower with fesotero-
dine €433 (411; 457) than with solifenacin [€533 (515; 552); p0.001] or tolterodine
[€563 (539; 585), p0.001]. Drug costs due to co-morbidities associated with OAB
were also lower with fesoterodine [€216 (180; 258)] compared with solifenacin [€305
(274; 338); p0.002] or tolterodine [€335 (306; 366), p0.001]. CONCLUSIONS: Treat-
ment of OAB with fesoterodine in clinical practice in Spain was a cost-saving ther-
apy from the NHS perspective as compared to solifenacin or tolterodine.
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OBJECTIVES: The present study aims to compare the work status and the indirect
costs associated to morbidity in end-stage renal disease patients undergoing one of
the following alternatives of renal replacement therapy (RRT): Hemodialysis in a
specialized center (HD), automated peritoneal dialysis (APD), continuous ambula-
tory peritoneal dialysis (CAPD), and renal transplant (TX). METHODS: An analysis
on indirect costs from morbidity on RRT was implemented, following the Human
Capital Theory. An epidemiological, multicenter, cross-sectional study was con-
ducted. A total of 243 patients in working age were included (32 CAPD, 46 APD, 83
HD and 82 TX). The potentially productive years of life lost (PPYL), the costs of lost
labor productivity (LLPc) for the year 2009 and the total cost of PPYL (PPYLtc) until
age of retirement were estimated. All the estimations were adjusted by age, sex and
different activity rates (obtained from the Spanish National Institute of Statistics).
Besides, discount rates of 0%, 3% and 6% were also considered. Chi2 tests and
Kruskal-Wallis or Mann-Whitney U (Bonferroni correction) statistics were used to
compare socio-demographic and clinical variables. Due to its skewed distribution,
non-parametric analysis (a bootstrap confidence intervals of differences in costs
calculated following the simple bias-corrected percentile method -1,000 bootstrap
estimates-) was computed to highlight differences in costs. RESULTS: No signifi-
cant differences were found in age or sex between groups (p0.05). The PPYL were:
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